Centanafadine, a new norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) was shown to be effective at treating ADHD in adults, teens, and kids during a Phase Three trial. The new ADHD drug requires FDA approval before it will be available for prescription in the United States.
